SPARC’s proprietary Nanotecton^TM technology is based on forming a complex of drug with polymer and lipids in an optimum ratio to achieve a ‘packing’ parameter that allows self-assembly of the composition into nanoparticles of 50-150 nm in size.

Nanotecton^TM technology involves producing a clear colourless solution of the Tectons (meaning “building blocks”) in a biocompatible, non-toxic solvent. Tectons are drug, lipids, and polymers.

When the solution is injected into dextrose injection it forms nanoparticles when solvent diffuses out in dextrose. It is believed that as solvent diffuses, the flexible coiled hydrophilic polymers are “pinned” to a hydrophobic drug and lipid molecules imparting amphipathic behaviour to the drugs and lipids.

The transiently formed amphipaths by their own nature preclude water and self-assemble as mixed micelles or compound mixed micelles (nanoparticles). The complementary functional interaction of “Tectons” leading to nanoparticle formation is termed Nanotecton^TM technology.

Nanotecton^TM technology is useful for water insoluble drugs and addresses the challenges associated with water insoluble drugs by providing higher drug localization to target site, lesser excipient to drug ratio, and ability to formulate higher dose of the drug.

This pioneering technology significantly enhances our capabilities by providing a more economical and efficient way of making nano-sized particles of water-insoluble drugs. It enables precision delivery of efficacious doses while protecting against adverse effects that would otherwise limit the use cytotoxic medicines. The technology is robust, scalable and applicable to a wide range of water-insoluble compounds. Using this technology, SPARC currently has several products in various stages of development in injectable dosage forms.

SPARC has been granted US Patent for its innovative platform technology that provides SPARC and its customers with a long-term competitive advantage up to 2029.